DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert Frederix et al.|The Lancet Oncology|2018Cited by 419
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal CancerSietske C. van Nassau, Lieke H. J. Simkens, Marinde J. G. Bond et al.|JAMA Network Open|2021Cited by 10